FDA warned www.weightcrunchshop.com about selling unapproved and misbranded semaglutide and oxycodone drugs to U.S. consumers online.
What happened
FDA reviewed the website www.weightcrunchshop.com and observed that it introduced unapproved and misbranded semaglutide and opioid drug products into interstate commerce. The site offered "Orsema 0.25 mg" and "Orsema 0.50 mg" injectables, "Ozempic" products advertised for sale without a prescription, and oxycodone 15 mg and 30 mg tablets advertised as available without a prescription. No inspection was described.
What FDA found
The website sold semaglutide drug products that are new drugs without FDA-approved applications.
FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]The semaglutide and oxycodone products were prescription drugs offered for sale without a prescription, misbranding them.
FD&C Act section 503(b)(1) and section 301(k) [21 U.S.C. §§ 353(b)(1), 331(k)]The products' labeling lacked adequate directions for use by a layperson, making them misbranded.
FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]The website introduced misbranded drugs into interstate commerce by offering them for sale to U.S. consumers.
FD&C Act section 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA requests that the company cease offering any unapproved and misbranded drugs for sale to U.S. consumers. The company must notify FDA in writing within 15 working days describing specific steps taken to address violations and prevent recurrence, or explain any delay.
Who should pay attention
- consumers buying semaglutide or opioid products online
- online pharmacies and websites selling prescription drugs to U.S. consumers
- legitimate makers or sellers of semaglutide and oxycodone products affected by counterfeit or unapproved copies
This is a summary. Read the original letter on fda.gov.